Insulin inhalers as good as injections, say firms
This article was originally published in Clinica
Executive Summary
Rival companies developing insulin inhalers for the noninvasive treatment of Type II diabetes have reported strong trial results for their respective devices, which are designed to avoid the pain and inconvenience of daily injections. Aerogen is confident about its hand-held Aerodose inhaler, while Aradigm has its hopes pinned on its AERx electronic insulin delivery system. Both devices could in time be achieving a share the US 17m diabetic patients' market.